To the Editor,
I read with interest your article entitled “Panel Grapples With the Role of Biosimilars in Oncology” that reported on The Atlantic’s panel discussion of June 1, 2018, on the role that biosimilars will play in cancer care.
Although you accurately reported comments from Mr. Andrew Spiegel of the Global Colon Cancer Association, I am concerned that some of his statements will perpetuate misconceptions about biosimilars. Mr. Spiegel stated that the European experience with biosimilars was inadequate because the European health authorities did not require pharmacovigilance reporting with the same rigor as required in the United States, suggesting that we do not have convincing data supporting the post-approval safety profile of biosimilars marketed in Europe.
These assertions are far from the truth.
There are many European Union member countries with sizable populations that have advanced pharmacovigilance systems that are as excellent as any pharmacovigilance system in the world.
Ever since the approval of Omnitrope (somatropin) in Europe in 2006 as the world’s first biosimilar, EU health authorities have subjected all EU-approved biosimilars to the very same pharmacovigilance reporting standards, post-approval studies and periodic re-analyses of benefit-risk profile as any other newly approved biological drug.
Based on the extensive and well-executed pharmacovigilance reporting associated with 700 million patient-days of exposure to biosimilars in the European Union,1 the European Medicines Agency (EMA) concluded in 2017 that “The EU monitoring system for safety concerns has not identified any relevant difference in the nature, severity or frequency of adverse effects between biosimilar medicines and their reference medicines.”2
Healthcare professionals and the public in the United States can be reassured: well-designed biosimilars approved to the standards of the FDA and EMA are as safe and effective for their intended use as their respective reference medicines.
References
1. Biosimilar Medicines Group, a Medicines for Europe sector group. Comment on the Food and Drug Administration Notice: Oncologic Drugs Advisory Committee meeting (Docket FDA-2017-N-2732). Regulations.gov. https://www.regulations.gov/document?D=FDA-2017-N-2732-0006. Published June 26, 2017. Accessed June 7, 2018.
2. European Medicines Agency. Biosimilars in the EU: Information guide for healthcare professionals. European Medicines Agency website. http://www.ema.europa.eu/docs/en_GB/document_library/Leaflet/2017/05/WC500226648.pdf. Published April 27, 2017. Accessed June 4, 2018.
Escaping the Void: All Things Biosimilars With Craig & G
May 4th 2025To close out the Festival of Biologics, Craig Burton and Giuseppe Randazzo from the Association for Accessible Medicines and the Biosimilars Council tackle the current biosimilar landscape and how the industry can emerge from the "biosimilar void."
Etanercept Biosimilar Switch Shows Stable Outcomes and Disease Control in RA
May 13th 2025Patients with rheumatoid arthritis (RA) who switched from Enbrel (reference etanercept) to a biosimilar maintained remission, even after their dose was reduced, with no signs of worsening based on clinical scores, ultrasound scans, or lab tests, according to a new study.
How AI Can Help Address Cost-Related Nonadherence to Biologic, Biosimilar Treatment
March 9th 2025Despite saving billions, biosimilars still account for only a small share of the biologics market—what's standing in the way of broader adoption and how can artificial intelligence (AI) help change that?
Switching From Avastin to Bevacizumab-bvzr in CRC, NSCLC Can Reduce Medicare Costs
May 10th 2025Monthly savings from fully converting Medicare patients with metastatic colorectal cancer (CRC) and non-squamous metastatic non-small cell lung cancer (NSCLC) from reference bevacizumab to bevacizumab-bvzr could fund 13,887 and 8,959 additional patient-months of treatment, respectively, according to a cost-effectiveness study.